AIBILI - Association for Innovation and Biomedical Research on Light and Image is a Research Technology Organisation in the health area dedicated to the development and clinical research of new products for medical therapy and diagnostic imaging.
It is a private non-profit organisation, founded in 1989, established to support translational research and technology transfer in the health area.
AIBILI is certified by ISO 9001 since 2004. It is certified for the following activities: performance of clinical studies; planning, coordination, monitoring of clinical research activities; health technology assessment; grading of eye exams; research and development in new technologies for medicine in the areas of imaging, optics and photobiology; preclinical studies of new molecules with potential medical use; and data centre activities.
AIBILI has the ECRIN Data Centre Certification, meeting the ECRIN requirements for IT and Data Management within clinical trials.
Clinical trials are performed in accordance with ICH Guidelines for Good Clinical Practice (GCP), European and national applicable legislations and regulations.
The European Clinical Research Infrastructure Network (ECRIN) announced that its 2017 celebration of International Clinical Trials Day (ICTD) will take place in Lisbon, Portugal on 19 May 2017. The theme of this year’s event is ‘Data sharing and reuse: attitudes and practices in multinational clinical research’. AIBILI will present two communications on Certified Data Centre and Pharmacovigilance in Clinical Trials. For more information please consult PtCRIN.
AIBILI has organized a workshop dedicated to OCT-Angiography on 07/04/2017. Please download here the programme.
Prof. José Cunha-Vaz talks to EUROTIMES about the crucial role played by the blood-retinal barrier (BRB) in the regulation of the micro-environment of the retina, with breakdown of the BRB directly implicated in the development of a range of retinal diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). Please see here the interview.